[Beneficial effects of probucol on endothelial function in patients with acute coronary syndrome].
OBJECTIVE
The study investigate the antioxidant probucol on endothelial function in patients with acute coronary syndrome (ACS).


METHODS
A total of 49 ACS patients randomly received standard therapy plus probucol (P, n = 24) or standard therapy (C, n = 25). Plasma oxidized low-density lipoprotein (ox-LDL), nitric oxide (NO) and circulating endothelial cells (CEC) were measured. The brachial arterial hyperemia-induced flow mediated dilation (FMD) and sublingual nitroglycerin (NTG) mediated vasodilatations were measured by high resolution ultrasound. These variables were analyzed before and after 3 months therapy.


RESULTS
Plasma NO and FMD was significantly increased after 3 months therapy than before therapy [(80.46 +/- 10.24) micromol/Lvs (48.46 +/- 12.24) micromol/L, P < 0.01; (13.46 +/- 1.20)% vs (7.45 +/- 1.02)%, P < 0.05, respectively], while the number of CEC and ox-LDL were significantly decreased (P < 0.01) in P group. These values were similar before and after 3 months in C group. The linear correlation analysis showed that plasma ox-LDL negatively correlated with NO (r = -0.574, P < 0.01) and FMD (r = -0.517, P < 0.01) and positively correlated with CEC (r = 0.385, P < 0.01) in patients received 3 months probucol therapy.


CONCLUSIONS
Chronic antioxidant probucol therapy could improve endothelial function in patients with ACS.
Dong
Hong-mei
HM
Institute of Cardiology, Xinqiao Hospital, the Third Military Medical University, Chongqing 400037, China.
Huang
Lan
L
Zhu
Shan-jun
SJ
Geng
Zhao-hua
ZH
Wu
Xiao-jing
XJ
Jin
Jun
J
Yu
Xue-jun
XJ
Qin
Jun
J
Xia
Hong-mei
HM
D000328:Adult; D000368:Aged; D000789:Angina, Unstable / Q000097:blood / Q000188:drug therapy*; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D042783:Endothelial Cells / Q000187:drug effects / Q000502:physiology; D004730:Endothelium, Vascular / Q000187:drug effects / Q000503:physiopathology*; D005260:Female; D006801:Humans; D008077:Lipoproteins, LDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000503:physiopathology; D009569:Nitric Oxide / Q000097:blood; D011341:Probucol / Q000627:therapeutic use*
D000924:Anticholesteremic Agents; D008077:Lipoproteins, LDL; D009569:Nitric Oxide; D011341:Probucol